Prognostic markers of survival in infants younger than 12 months vertically infected by human immunodeficiency virus type-1;Marcadores predictivos de supervivencia en niños menores de 12 meses de edad infectados verticalmente por el virus de la inmunodeficiencia humana

Medicina Clinica

Volumn 113, Issue 15, 1999, Pages 561-566

  Resino, Salvador ^a   Jiménez, José Luis ^a   Gurbindo, Dolores ^a   Muñoz Fernández, Ma Ángeles ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

Biological phenotype; CD4+ T lymphocyte; HIV RNA viral load; HIV 1; Infants; Prognostic markers; Survival

Indexed keywords

BIOLOGICAL MARKER;

AGE; ARTICLE; DISEASE COURSE; DISEASE TRANSMISSION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; INFANT; MALE; MORTALITY; NEWBORN; PATHOPHYSIOLOGY; PHENOTYPE; PREGNANCY; PREGNANCY COMPLICATION; PROGNOSIS; PROSPECTIVE STUDY; RESIDENTIAL CARE; RISK FACTOR; SPAIN; STATISTICS; SURVIVAL RATE;

AGE FACTORS; BIOLOGICAL MARKERS; CATCHMENT AREA (HEALTH); DISEASE PROGRESSION; DISEASE TRANSMISSION, VERTICAL; FEMALE; HIV SEROPOSITIVITY; HIV-1; HUMANS; INFANT; INFANT, NEWBORN; MALE; PHENOTYPE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS; SPAIN; SURVIVAL RATE;

EID: 0033530316     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Mellors JW, Muñoz A, Giorgi JV, Morgolick JB, Tassoni CJ, Gupta P. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997; 126: 946-954.
2. O'Brien WA, Hartigan PM, Martin D, Esinhart J, Hill A, Benorts et al. Changes in plasma HIV-1 RNA+ and CD4+ lymphocytes counts and the risk of progression to AIDS. N Engl J Med 1996; 334: 426-431.
3. The European Collaborative Study Pediatric Infect Dis J. Age-related standards for lymphocyte subsets based on uninfected children born to HIV infected women. J Infect Dis 1992; 11: 1.018-1.026.
4. Blanches S, Newell M, Mayaux M, Dunn AT, Teglas JP, Rouzioux C et al. Morbidity and mortality in European Children vertically infected by HIV-1: the French prospective study and the European collaborative study. J Acquir Immune Def Syndrome 1997; 14: 1.442-1.450.
5. Mofenson LM, Korelitz J, Meyer WA III, Bethel J, Rich K, Pahwa S et al. The relationship between serum HIV-1 RNA levels, CD4 lymphocyte percent, and long-term mortality risk in HIV-1 infected children. J Infect Dis 1997; 175: 1.029-1.038.
6. Shearer WT, Quinn TC, La Russa P, Lew JF, Mofenson L, Almy S et al. Viral load and disease progression in infants infected with human immunodeficiency virus tipe 1. N Engl J Med 1997; 336: 1.337-1.342.
7. Palumbo PE, Raskino C, Fiscus S, Pahwa S, Fowler MG, Spector SA et al. Predictive value of quantitative plasma HIV RNA and CD4+-lymphocyte count in HIV-1 infected infants and children. JAMA 1998; 11 279: 756-761.
8. Valentine ME, Jackson CR, Vavro C, Wilfertom, Mc Clernon D, St. Clair M. Evaluation of surrogate markers and clinical outcomes in two-years follow-up of eighty-six human immunodeficiency virus-infected pediatric patients. Pediatr Infect Dis J 1998; 17: 18-23.
9. Muñoz-Fernández MA, Resino S, Navarro J, Obregón E, Jiménez JL, Alonso R et al. High viral load in children long-term non progresser vertically infected with HIV-1. Immunologic characterization. En: 12th World AIDS Conference Book. Geneve (Switzerland), June 28-July 3, 1998. Bolonia: Monduzzi Editore S.P A., 1998; 2: 45-49.
10. Tersmette M, Lange JM, De Goede RE, De Wolf F, Feftink-Shattenkerk JK, Schellekens PT et al. Association between biological properties of human immunodeficiency virus variant and risk for AIDS mortality. Lancet 1989; 6: 983-985.
11. Schuitemaker H, Koot M, Kootstra NA, Derksen MW, De Goede RE, Van Steenwijk RP et al. Biological phenotype of human immunodeficiency virus tipe 1 clones at different stages of infection: progression of the disease is associated with a shift from monocytotropic to T-cell-tropic virus population. J Virol 1992; 66: 1.354-1.360.
12. Muñoz-Fernández MA, Obregón E, Navarro J, Borner C, Gurbindo MD, Sampelayo TH et al. Relationship of virological, immunological, and clinical parameters in infants with vertically acquired human immunodeficiency virus tipe 1 infection. Pediat Res 1996; 40: 597-602.
13. Balotta C, Vigano A, Riva C, Colombo MC. HIV type 1 phenotype correlates with the stage of infection in vertically infected children. AIDS Res Hum Retrovir 1996; 12: 1.247-1.253.
14. Pediatric European Network for Treatment of AIDS (PENTA). HIV-1 viral load and CD4 cell count in untreated children with vertically acquired asymptomatic or mild disease. AIDS 1998; 12: F1-F8.
15. Muñoz-Fernández MA, Navarro J, Garcia Montes M, Cosín J, Zabay JM, Fernández-Cruz E. Quantification of low levels of HIV-1 RNA viremia in p24-antigen negative asymtomatic HIV+ patients by use of the polymerase chain reaction. J Clin Microbiol 1996; 34: 404-408.
16. Matthews JN, Altman DG, Campbell MJ, Royston P. Analysis of serial measurements in medical research. Br Med J 1990; 300: 230-235.
17. Cox DR. Regression models and life tables. J R Stat Soc 1972; 34:187-220.
18. Center for Diseases Control and Prevention. Revised classification system for HIV-1 infection in children less than 13 years of age. MMWR 1994; 43: 1-13.
19. Luzuriaga K, McQuilken P, Alimenti A, Somasundaron M, Hessetton R, Sullivan JL et al. Early viremia and immune responses in vertical human immunodeficiency virus type 1 infection. J Infect Dis 1993; 167: 1.008-1.013.
20. Dickover RE, Dillon M, Gillette SG, Deveikis A, Keller M, Plaeger-Marshall S et al. Rapid ncreases in load of human immunodeficiency virus correlate with early progression and loss of CD4 cells in vertically infected infants. J Infect Dis 1994; 170: 1.279-1.284.
21. Englund JA, Baker CJ, Raskino C, McKinney RE, Petrie B, Fowler MG et al. Zidovudine, didanosine, or both as the initial treatment for symptomatic HIV-infected children. N Engl J Med 1997; 336: 1.704-1.712.
22. Katlama C, Ingrand D, Loveday C, Clumeck N, Mallolas J, Straszewski S et al. The lamivudine European HIV Working Group, et al. Safety and efficacy of lamivudine (3TC)/Zidovudine (ZDV) in antirretroviral naive HIV-1 infected patients: a comparison with zidovudine monotherapy. J Am Med Assoc 1996; 276: 118-125.
23. Pizzo PA, Wilfert CM, The Pediatric AIDS Siena Workshop II. Markers and determinants of disease progression in children with HIV infection. J AIDS 1995; 8: 30-44.
24. Koot M, Keet IP, Vos AH, De Goedere, Roos MT, Coutinho RA et al. Prognostic value of HIV-1 biological phenotype for rate of CD4+ count cell depletion and progression to AIDS. Ann Intern Med 1993; 118: 681-688.
25. Muñoz-Fernández MA, Navarro J, Obregón E, Arias RA, Gurbindo MD, Sampelayo TH et al. Immunological and virological markers of disease progression in HIV-1 infected children. Acta Paediatr Suppl 1997; 421:46-51.
26. Balotta C, Colombo MC, Colucci G, Vigano A, Riva C, Papagno L et al. Plasma viremia and virus phenotype are correlates of disease progression in vertically human immunodeficiency virus type 1-infected children. Pediatr Infect Dis 1997; 16: 205-211.
27. Gupta P, Urbach A, Cosentino L, Thampatty P, Brady M. HIV-1 isolates from children with or without AIDS have a similar in vitro biological properties. AIDS 1993; 7: 1.561-1.564.
28. Cartón JA, Melón S, Maradona JA, De Oña M, Asensi V, Martínez A et al. Replication indexes of the human immunodefiency virus: predictive valve of viral culture and blood antigens. Med Clin (Barc) 1994; 102.
29. Connor RI, Ho DD. Human immunodeficiency virus type 1 variants with increased replicative capacity develop during asymptomatic stage before disease progression. J Virol 1994; 68: 4.400-4.408.
30. Straszewski S, Miller V, Rehmet S, Stark T, De Cree J, De Brabander M et al. Virological and immunological analysis of a triple combination pilot study with loviride, Iamivudine and zidovudine in HIV-1 infected patients. AIDS 1996; 10: F1-F7.